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Mycobacterium tuberculosis Rv0652 stimulates production of
tumour necrosis factor and monocytes chemoattractant protein-1
in macrophages through the Toll-like receptor 4 pathway
Introduction
Mycobacterium tuberculosis is the causative agent of tuber-
culosis (TB), a major global disease responsible for 2
million deaths annually.1 The emergence of multi-drug-
resistant strains, the increased number of cases of reactive
TB in immunocompromised patients such as those with
AIDS, and the variable efficacy of the only currently avail-
able vaccine, bacillus Calmette–Gue´rin,2 have prompted
the development of novel control strategies for TB. The
identification and characterization of immune-modulating
mycobacterial proteins are essential for understanding
TB pathogenesis and for developing new TB eradication
strategies.
Macrophages constitute the first line of defence against
M. tuberculosis and are critical in linking innate and adap-
tive immunity.3 Macrophages infected with M. tuberculo-
sis are activated to release various pro-inflammatory
cytokines and chemokines, thereby promoting lymphocyte
activation and recruitment, and ultimately inducing gran-
uloma formation.4 Despite robust immune responses,
M. tuberculosis survives within macrophages by modulat-
ing their antimycobacterial activity. Proteins secreted by
live M. tuberculosis within macrophages elicit protective
immunity or interfere with the microbicidal function of
macrophages.
During M. tuberculosis infection, pro-inflammatory
cytokines such as tumour necrosis factor (TNF) and
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Summary
Mycobacterial proteins interact with host macrophages and modulate
their functions and cytokine gene expression profile. The protein Rv0652
is abundant in culture filtrates of Mycobacterium tuberculosis K-strain,
which belongs to the Beijing family, compared with levels in the H37Rv
and CDC1551 strains. Rv0652 induces strong antibody responses in
patients with active tuberculosis. We investigated pro-inflammatory cyto-
kine production induced by Rv0652 in murine macrophages and the roles
of signalling pathways. In RAW264.7 cells and bone marrow-derived mac-
rophages, recombinant Rv0652 induced predominantly tumour necrosis
factor (TNF) and monocyte chemoattractant protein (MCP)-1 production,
which was dependent on mitogen-activated protein kinases and nuclear
factor-jB. Specific signalling pathway inhibitors revealed that the extracel-
lular signal-regulated kinase 1/2 (ERK1/2), p38 and phosphatidylinositol
3-kinase (PI3K) pathways were essential for Rv0652-induced TNF produc-
tion, whereas the ERK1/2 and PI3K pathways, but not the p38 pathway,
were critical for MCP-1 production in macrophages. Rv0652-stimulated
TNF and MCP-1 secretion by macrophages occurred in a Toll-like recep-
tor 4-dependent and MyD88-dependent manner. In addition, Rv0652 sig-
nificantly up-regulated the expression of the mannose receptor, CD80,
CD86 and MHC class II molecules. These results suggest that Rv0652 can
induce a protective immunity against M. tuberculosis through the macro-
phage activation.
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interleukin-12 (IL-12) as well as chemokines are essential
for anti-mycobacterial activity and granuloma formation.5
Macrophages recognize M. tuberculosis and its compo-
nents via pattern-recognition receptors such as Toll-like
receptors (TLRs). In response, macrophages become acti-
vated and secrete cytokines and chemokines.6 Various
mycobacterial proteins and glycolipids involved in the
responses through the TLR pathway have been identified.
For example, a 19 000 molecular weight (MW) protein
was shown to activate macrophages to secrete TNF and
nitric oxide,7 and to inhibit MHC class II antigen pro-
cessing via an interaction with TLR2.8 In addition, recent
reports indicated that PPE18 interacts with TLR2 to acti-
vate IL-10 production in macrophages,9 and that a 38 000
MW protein acts through both TLR2 and TLR4 to induce
the production of pro-inflammatory cytokines.10 Among
mycobacterial PE/PPE proteins, PE_PGRS33, PE_PGRS11,
and PE_PGRS17 were shown to interact with TLR2.11,12
Also glycolipids such as lipoarabinomannan, lipomannan
and glycopeptidolipids interact with TLR2. 13,14 However,
little is known about mycobacterial proteins that activate
macrophages via TLR4.
Mycobacterial proteins recognized by a host immune
system are interesting targets for the development of new
vaccines and diagnostic reagents. Recently, we reported
that Rv0652, the 50S ribosomal proteins L7/L12, elicits a
strong serum antibody response in patients with active
TB.15 This protein is one among purified protein deriva-
tive proteins that induce strong delayed-type hypersensi-
tivity.16 A proteomics analysis revealed that this protein
was abundant in culture filtrates of M. tuberculosis
K-strain, and not in those of M. tuberculosis H37Rv and
CDC1551.17 The K-strain, which is the most prevalent
strain in Korea, belongs to the Beijing family and is con-
sidered to be highly virulent.18 Interestingly, microbial
ribosomal proteins are known to be potent adjuvants.19,20
Nevertheless, there is no report of the effect of Rv0652 on
macrophage activation and related signalling events.
In this study, we investigated the immunostimulatory role
of Rv0652 in murine macrophages. Our data suggest that
recombinant Rv0652 activates macrophages to secrete pro-
inflammatory cytokines, predominantly TNF and monocyte
chemoattractant protein 1 (MCP-1), through TLR4-depen-
dent and MyD88-dependent signalling pathways. Further-
more, Rv0652 significantly up-regulated the expression of
mannose receptor (MR), CD80 (B7-1), CD86 (B7-2), and
MHC class II molecules, compared with expression levels in
untreated cells.
Materials and methods
Reagents and antibodies
Enzyme-linked immunosorbent assay (ELISA) kits for the
detection of TNF, MCP-1 and IL-1b were obtained from
eBioscience (San Diego, CA), and ELISA kits for IL-12p70
and IL-10 were obtained from BD Biosciences (San
Diego, CA). Anti-phosphorylated extracellular signal-reg-
ulated kinase 1/2 (ERK1/2), anti-phosphorylated p38,
anti-phosphorylated Akt, anti-IjBa, and anti-b-actin
monoclonal antibodies, and anti-p38 and anti-ERK1/2
polyclonal antibodies were obtained from Cell Signaling
Technology, Inc. (Beverly, MA). Horseradish peroxidase-
conjugated anti-mouse IgG, horseradish peroxidase-
conjugated anti-rabbit IgG, and specific inhibitors of
ERK (U0126), p38 mitogen-activated protein kinase
(MAPK; SB203580), phosphatidylinositol 3-kinase (PI3K;
LY294002), and nuclear factor-jB (NF-jB; BAY 11-7082)
were obtained from Calbiochem (San Diego, CA). Fluo-
rescein isothiocyanate-conjugated monoclonal antibody
against MHC class II, phycoerythrin-conjugated monoclo-
nal antibodies against MR and CD86, and allophycocya-
nin-conjugated monoclonal antibody against CD80 were
purchased from BD Biosciences.
Mice
Male C57BL/6 (H-2Kb and I-Ab) mice, 6–8 weeks old, were
purchased from the Korean Institute of Chemistry Tech-
nology (Daejeon, Korea). C57BL/6J TLR2 knockout (KO)
mice (TLR2)/); B6.129-Tlr2tm1Kir/J), C57BL/10 TLR4 KO
mice (TLR4)/); C57BL/10ScNJ), and C57BL/6J MyD88
KO mice [MyD88)/); B6.129P2(SJL)-MyD88tml.Defr/J] aged
6–8 weeks were purchased from Jackson Laboratories (Bar
Harbor, ME). All mice were housed in a specific pathogen-
free environment in an animal facility for at least 1 week
before the experiments. The animal procedures were
approved by the Institutional Animal Care and Use Com-
mittee of Chungnam National University (Permit Number:
2010-3-9), and all animal experiments were performed in
accordance with Korean Food and Drug Administration
guidelines.
Purification of recombinant Rv0652 protein and
antigen 85 complex (Ag85)
Recombinant Rv0652 protein was prepared as described
previously.15 In brief, the recombinant plasmid encoding
the Rv0652 gene was transformed into Escherichia coli
BL21 (DE3) for protein over-expression. The recombinant
protein was purified by nickel nitrilotriacetic acid agarose
(Ni-NTA) chromatography in accordance with the manu-
facturer’s instructions (Invitrogen, Carlsbad, CA). The
purity of the prepared protein was analysed by SDS–
PAGE, followed by Coomassie blue staining or immuno-
blotting using anti-His antibodies (Invitrogen). Purified
Rv0652 protein was dialysed against PBS to remove imid-
azole and was then incubated overnight at 4 with poly-
myxin B-agarose beads (Sigma-Aldrich, St Louis, MO) to
remove endotoxin contamination. Further evaluation of
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bacterial endotoxin was carried out using an amoebocyte
lysate assay (Sigma-Aldrich). The purified protein was
stored in small aliquots at )80 until used.
Native Ag85 was purified from the culture filtrate of
M. tuberculosis H37Rv (ATCC 27294) by ammonium sul-
phate precipitation, followed by hydroxyapatite and anion
exchange chromatography, as described previously.21
Cell culture and generation of bone-marrow derived
macrophages
The RAW264.7 macrophage cell line was cultured in Dul-
becco’s modified Eagle’s medium (DMEM; Lonza, Walkers-
ville, MD) supplemented with 10% fetal bovine serum
(FBS; Hyclone, Logan, UT), 1% HEPES, and 1% L-gluta-
mine at 37 in an atmosphere of 5% CO2. Bone-marrow-
derived macrophages (BMDM) were obtained from C57BL/
6 and all KO mice. Briefly, bone marrow cells from the
femur and tibia were cultured in DMEM containing 2 mM
L-glutamine, 100 U/ml penicillin, 100 lg/ml streptomycin,
10% FBS and 25 ng/ml recombinant mouse macrophage
colony-stimulating factor (R&D Systems, Minneapolis,
MN) at 37 in an atmosphere of 5% CO2. After 4 days,
non-adherent cells were removed, and differentiated macro-
phages were incubated in antibiotic-free DMEM.
Cell cytotoxicity analysis
RAW264.7 cells were seeded at a density of 1 · 104 per
well in 96-well culture plates and treated with Rv0652
(10 lg/ml). After 24 or 48 hr, cell viability was assessed
using a Cell Counting Kit-8 (CCK-8; Dojindo Laboratory,
Kumamoto, Japan). Aliquots of the kit reagent were
added to the culture medium, and the plate was incu-
bated at 37 for another hour. Cell viability was deter-
mined as absorbance at 450 nm with a microplate reader.
Measurement of cytokines and chemokines by ELISA
Culture supernatants of macrophages stimulated with
Rv0652 or lipopolysaccharide (LPS) were harvested at
the indicated time-points and stored at )20. Sandwich
ELISAs were used to detect cytokine and chemokine levels
in the culture supernatants. The assays were performed as
recommended by the manufacturers (eBioscience and BD
Biosciences). The cytokine concentrations were calculated
using standard curves that were generated from recombi-
nant cytokines.
LPS contamination assay in the Rv0652 preparation
Before stimulating with Rv0652, the protein preparation
was heat denatured at 100 for 30 min or treated with
proteinase K (1/20 concentration of protein) for 1 hr;
proteinase K was inactivated by boiling. We also deter-
mined whether Rv0652-induced macrophage activation
was neutralized by incubation with polymyxin B (10 lg/
ml) for 30 min.
Determination of MAPK phosphorylation
The BMDM stimulated with Rv0652 for the times indicated
were detached, collected by centrifugation, and lysed in
lysis buffer (10 mM Tris–HCl, pH 74, 5 mM EDTA,
150 mM NaCl, 1% Triton X-100, 1 mM PMSF, and protease
inhibitor cocktail). Protein concentrations were determined
with the Bradford assay, and 30 lg of protein were sepa-
rated by SDS–PAGE, followed by electrotransfer to a nitro-
cellulose membrane (Hybond-ECL; GE Healthcare, Little
Chalfont, UK). The blots were probed with an appropriate
primary antibody (anti-phospho-ERK, anti-ERK, anti-
phospho-p38, anti-p38, anti-phospho-Akt, anti-IjBa, or
anti-b-actin) at the optimized concentration, followed by
horseradish peroxidase-conjugated secondary antibody.
Immunoreactive bands were detected by enhanced
chemiluminescence (ECL; GE Healthcare) and exposure to
film.
To determine the effects of pharmacological inhibitors
on Rv0652-induced TNF and MCP-1 production, BMDM
were incubated with an inhibitor of ERK (U0126,
5–20 lM), p38 (SB203580, 5–20 lM), PI3K (LY294002, 5–
20 lM), or NF-jB (BAY 11-7082, 5–20 lM), reconstituted
in sterile cell culture-grade DMSO (Sigma-Aldrich), for
1 hr before treatment with Rv0652 (5 lg/ml). As a con-
trol, 01% (volume/volume) DMSO was added to some
samples. After incubation for 24 hr, the TNF-a and
MCP-1 levels were measured by ELISA.
Flow cytometric analysis of surface molecules in
macrophages
RAW264.7 macrophages were stimulated with Rv0652
(5 lg/ml), LPS (100 ng/ml), or Ag85 (5 lg/ml). After incu-
bation for 24 hr, the cells were harvested, washed with PBS,
and suspended in FACS wash buffer (2% FBS and 01%
sodium azide in PBS). The cells were pre-incubated with
05% BSA in PBS for 30 min and washed with PBS. The
cells were then stained with fluorescein isothiocyanate-con-
jugated anti-MHC class II antibody or phycoerythrin-con-
jugated anti-MR, anti-CD86, or anti-CD80 antibody for
45 min at 4. After the cells were washed three times with
PBS and resuspended in 500 ll PBS, flow cytometric analy-
sis was performed (FACSCanto, BD Biosciences). The data
were analysed using CELL QUEST software (Becton Dickin-
son, San Jose, CA).
Statistical analysis
The data are presented as means ± standard deviation
(SD) from at least three independent experiments. Statis-
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tical analyses were performed using an unpaired Student’s
t-test with Bonferroni adjustment. Significance was indi-
cated by a P-value of < 005.
Results
Purification of recombinant Rv0652 protein
Rv0652 was expressed as a His-tagged protein in E. coli
and purified by Ni-NTA affinity chromatography. The
purified protein appeared as a major band at approxi-
mately 23 000 MW, although faint contaminating bands
were also observed (Fig. 1). The 23 000-MW band reacted
with anti-His antibody on an immunoblot (data not
shown). Its purity was > 97% based on SDS–PAGE.
Rv0652 protein induces the secretion of
pro-inflammatory cytokines and MCP-1
To assess whether Rv0652 can stimulate a macrophage
response, its ability to induce cytokine production in
macrophages was determined. Cytotoxicity of Rv0652 to
RAW264.7 cells was tested using a Cell Counting Kit-8.
As shown in Fig. 2, no cytotoxic effect of Rv0652 at the
tested concentration was observed after 48 hr. The levels
of TNF, IL-1b, IL-12p70, IL-10 and MCP-1 in the culture
supernatant of BMDM treated with Rv0652 at 5 lg/ml
were determined. TNF, MCP-1, IL-12p70 and IL-10 were
detected 24 hr after stimulation (Fig. 3). TNF and
MCP-1 predominated, with Rv0652-stimulated TNF and
MCP-1 levels increasing in a time-dependent and dose-
dependent manner (Fig. 4). Production of TNF was
noted after 3 hr, and MCP-1 was detected after 18 hr.
Both were produced maximally at an Rv0652 concentration
of 5 lg/ml.
The pattern of cytokine production stimulated by
Rv0652 was similar to that stimulated by LPS, which was
used as a positive control (Fig. 3). We therefore tested
whether Rv0652-induced macrophage activation was
attributable to LPS contamination. Proteinase K diges-
tion or heat denaturation of the Rv0652 preparation
abrogated MCP-1 and TNF production (Fig. 5). Further-
more, pre-incubation of BMDM with polymyxin B for
30 min did not suppress Rv0652-induced MCP-1 or
TNF production, but did reduce the stimulatory effects
of LPS. These results verify that macrophage activation
was induced by intact Rv0652 and was not the result of
LPS contamination. In fact, the endotoxin content of the
purified recombinant Rv0652 was extremely low
(< 005 EU/ml).
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Figure 1. SDS–PAGE analysis of purified Rv0652 protein. The pro-
tein was expressed in Escherichia coli and purified by Ni-NTA affinity
chromatography. The gel was stained with Coomassie blue.
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Figure 2. Rv0652 is not cytotoxic to
RAW264.7 cells (a) and bone-marrow-derived
macrophages (BMDM) (b). RAW264.7 cells
and BMDM were treated with Rv0652 (10 lg/
ml) or lipopolysaccharide (LPS; 100 ng/ml) for
24 or 48 hr. Cell viability was measured using
a CCK-8 assay. Data are presented as
means ± SD of three experiments. MC, med-
ium control.
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Figure 3. Rv0652-induced cytokine and chemokine production in
bone-marrow-derived macrophages (BMDM). BMDM were stimu-
lated with Rv0652 (5 lg/ml) or lipopolysaccharide (LPS; 100 ng/ml)
for 24 or 48 hr. Levels of tumour necrosis factor (TNF), interleukin-
1b (IL-1b), IL-12p70, IL-10 and monocyte chemoattractant protein
1 (MCP-1) in culture medium were measured by ELISA. Data are
presented as means ± SD of three experiments. MC, medium
control.
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Figure 4. Rv0652-stimulated production of
tumour necrosis factor (TNF) and monocyte
chemoattractant protein 1 (MCP-1) in a time-
dependent and dose-dependent manner in
RAW264.7 cells. (a) RAW264.7 cells were stim-
ulated with Rv0652 (5 lg/ml) for the times
indicated. (b) RAW264.7 cells were stimulated
with Rv0652 at the concentrations indicated
for 18 hr. Levels of TNF and MCP-1 in culture
medium were measured by ELISA. Data are
presented as means ± SD of three experiments.
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Figure 5. Rv0652-induced tumour necrosis factor (TNF) and mono-
cyte chemoattractant protein 1 (MCP-1) production is not the result
of lipopolysaccharide (LPS) contamination. Bone-marrow-derived
macrophages (BMDM) were stimulated with Rv0652 (5 lg/ml),
heat-treated Rv0652, or proteinase K (PK)-treated Rv0652. The
BMDM were also incubated with polymyxin B (PMB, 10 lg/ml) for
30 min before treatment with Rv0652 (5 lg/ml) or LPS (100 ng/ml).
Culture supernatants were harvested after 24 hr, and the levels of
TNF and MCP-1 were measured by ELISA. Data are presented as
means ± SD of three experiments. ***P < 0001 versus untreated
(UT) control. MC, medium control.
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Rv0652 protein leads to MAPK phosphorylation
The MAPK are critical for cellular responses to many
external stimuli and are important signal molecules for
production of pro-inflammatory cytokines in M. tubercu-
losis-infected macrophages.6,22 We examined the activa-
tion of MAPK in response to Rv0652. Phosphorylation
profiles of ERK1/2, p38 and Akt in BMDM were analysed
at various time-points (15–240 min) after stimulation
with Rv0652. At 15 min after stimulation, ERK1/2, p38
MAPK and Akt were strongly phosphorylated (Fig. 6a).
In addition, the expression of IjBa was rapidly lost at
15 min and then reappeared. These results suggest that
Rv0652-induced macrophage activation is mediated by
signalling pathways involving MAPKs and NF-jB.
To examine the role of MAPKs in Rv0652-induced
MCP-1 and TNF production, BMDM were pre-treated
with a specific inhibitor of ERK1/2 (U0126), p38
(SB203580), PI3K (LY294002), or NF-jB (BAY 11-7082)
for 1 hr, and cytokine levels were assayed at 24 hr. As
shown in Fig. 6(b), TNF production in Rv0652-treated
BMDM was significantly inhibited by the ERK1/2, PI3K
and p38 MAPK inhibitors in a dose-dependent manner.
The LPS-induced TNF production was significantly inhib-
ited by the p38 inhibitor, and moderately inhibited by a
high concentration of the ERK1/2 and PI3K inhibitors. In
contrast, Rv0652-stimulated and LPS-stimulated MCP-1
production by BMDM was significantly depressed by the
ERK1/2 and PI3K inhibitors, and the p38 inhibitor
SB203580 significantly increased Rv0652-stimulated and
LPS-stimulated MCP-1 production. The production of
TNF and MCP-1 was completely abrogated by the NF-jB
inhibitor. The observed inhibition was not caused by
DMSO, because DMSO alone did not exhibit any inhibi-
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Figure 6. Rv0652 induces phosphorylation of mitogen-activated protein kinases (MAPK). (a) Bone-marrow-derived macrophages (BMDM) stim-
ulated with Rv0652 for the times indicated were lysed, and the proteins in the total cell lysate samples were separated by SDS–PAGE, followed by
immunoblot analysis using antibodies against phospho-extracellular signal-regulated kinase 1/2 (ERK1/2), ERK1/2, phospho-p38, p38, phospho-
Akt, IjBa, and b-actin. This image is representative of three experiments showing similar results. (b) Effect of MAPKs, p38, phosphatidylinositol
3-kinase (PI3K) and nuclear factor-jB (NF-jB) inhibitors on lipopolysaccharide (LPS) -induced and Rv0652-induced tumour necrosis factor
(TNF) and monocyte chemoattractant protein 1 (MCP-1) production. BMDM were treated with inhibitors of ERK (U0126, 5–20 lm), p38
(SB203580, 5–20 lm), PI3K (LY294002, 5–20 lm), or NF-jB (BAY 11-7082, 5–20 lm) for 1 hr before treatment with Rv0652 (5 lg/ml). After
24 hr, the levels of TNF and MCP-1 were measured by ELISA. Data are presented as means ± SD of three experiments. **P < 001 and
***P < 0001 versus untreated controls. MC, medium control; UT, untreated control.
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tory effects (data not shown). These results suggest that
the ERK1/2, p38 and PI3K pathways are critical for
Rv0652-induced TNF production, whereas ERK1/2 and
PI3K are required for MCP-1 production.
Rv0652-mediated induction of TNF and MCP-1 is
dependent on signalling via TLR4 and MyD88
Various mycobacterial proteins activate macrophages
through TLR2 and/or TLR4-dependent signals.6 To deter-
mine whether Rv0652-induced macrophage activation is
TLR-dependent, we prepared BMDM from C57BL/6J
wild-type (WT) and TLR2)/) mice, and C57BL/10 WT
and TLR4)/) mice, treated the BMDM with Rv0652
(5 lg/ml), Pam3 (100 ng/ml) or LPS (100 ng/ml) for
24 hr, and then measured the TNF and MCP-1 levels in
the culture supernatants, by ELISA. As shown in Fig. 7(a),
TNF and MCP-1 were produced in BMDM from TLR2)/
) and WT mice after stimulation with Rv0652. As
expected, the response to Pam3, TLR2 agonist, was signif-
icantly depressed in TLR2)/) mice. Interestingly, the
response to Rv0652 was significantly depressed in TLR4)/
) mice, which was similar to the response to LPS. These
findings suggest a specific role for TLR4 in Rv0652-
induced macrophage activation.
We also tested the MyD88-dependence of the response
to Rv0652 in BMDM prepared from C57BL/6J WT and
MyD88)/) mice. As shown in Fig. 7(b), Rv0652-induced
and LPS-induced production of TNF and MCP-1 were
significantly depressed in BMDM from MyD88)/) mice.
Rv0652 induces expression of surface molecules
related to macrophage function
Finally, we examined whether Rv0652 had a modulatory
role in the expression of macrophage surface molecules
such as MR, CD80, CD86 and MHC class II, which are
important for the function of macrophages as antigen-
presenting cells and phagocytes. RAW264.7 cells were
treated with Rv0652 (5 lg/ml) or LPS (100 ng/ml), and
after 24 hr, expression was examined by two-colour or
three-colour flow cytometry. Native Ag85 (5 lg/ml)
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Figure 7. Rv0652 stimulates tumour necrosis
factor (TNF) and monocyte chemoattractant
protein 1 (MCP-1) release in a Toll-like recep-
tor 4 (TLR4) -dependent and MyD88-depen-
dent manner. (a) Bone-marrow-derived
macrophages (BMDM) from C57BL/6J wild-
type (WT), TLR2)/), C57BL/10 WT, and
TLR4)/) mice were stimulated with Rv0652
(5 lg/ml), Pam3 (100 ng/ml), or lipopolysac-
charide (LPS; 100 ng/ml) for 24 hr. The levels
of TNF and MCP-1 in the culture supernatants
were measured by ELISA. (b) BMDM from
C57BL/6J WT and MyD88)/) mice were stim-
ulated with Rv0652 (5 lg/ml) or LPS (100 ng/
ml) for 24 hr. The levels of TNF and MCP-1
in the culture supernatants were measured by
ELISA. Data are presented as means ± SD of
three determinations. ***P < 0001 versus
BMDM from WT mice.
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served as a mycobacterial control protein. Ag85, the
major protein secreted by M. tuberculosis, has fibronectin-
binding activity and is strongly immunoreactive.21,23
Rv0652 and LPS significantly up-regulated the expression
of MR, CD80 and MHC class II molecules compared with
levels in untreated cells (Fig. 8), and Ag85 induced signif-
icant expression of MHC class II molecules. However, the
expression of CD86 was increased significantly only by
stimulation with Rv0652. Rv0652 more effectively induced
the expression of these surface molecules than did LPS.
Hence, in addition to stimulating the production of pro-
inflammatory cytokines, Rv0652 can influence the func-
tion of macrophages as antigen-presenting cells.
Discussion
The present investigation aimed to determine the regula-
tory mechanism of Rv0652 in macrophage activation.
Macrophages contribute directly to protective immunity
against M. tuberculosis through the production of pro-
inflammatory cytokines and chemokines. Mycobacterial
proteins interact with host macrophages and modulate
their functions and cytokine gene expression profile.
Rv0652 activates macrophages to release predominantly
TNF and MCP-1 through TLR4 signalling. Chemokines
recruit immune cells by chemotaxis and activate leuco-
cytes during inflammatory disease. In addition, MCP-1
substantially contributes to host antimycobacterial inflam-
matory responses.24 TNF is essential for maintaining
granulomas and controlling TB; mice with a deficiency in
TNF or its receptors are more susceptible to mycobacte-
rial infection.25,26 On the other hand, intracellular survival
of M. tuberculosis and its products stimulate continuous
production of the inflammatory mediators including
TNF, chemokines, nitric oxide and reactive oxygen inter-
mediates from macrophages, and eventually induce tissue
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Figure 8. Rv0652 induces the expression of
macrophage surface molecules on RAW264.7
macrophages. RAW264.7 cells were cultured
for 24 hr in the presence of Rv0652 (5 lg/ml),
Ag85 (5 lg/ml), or LPS (100 ng/ml), and the
expression of the surface markers MR, CD80,
CD86 and MHC class II was analysed by flow
cytometry. Data are representative of three
experiments showing similar results. Mean flu-
orescence intensities (MFI) calculated from
histograms are presented as means ± SD of
three independent experiments. *P < 005 or
**P < 001 or ***P < 0001 versus untreated
cells.
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damage. Hence, our data suggest that Rv0652 can induce
a protective immunity and also may be involved in TB
pathogenesis through inducing TNF and MCP-1 produc-
tion by macrophages.
Macrophage activation in response to mycobacteria and
their antigens initiates MAPK signalling pathways, result-
ing in inflammatory mediator production.6 In the present
study, TNF-a production by macrophages stimulated with
Rv0652 required the ERK1/2, p38 and PI3K pathways,
whereas MCP-1 production required ERK1/2 and PI3K.
In contrast to TNF, MCP-1 production was significantly
increased by pre-incubation with a p38 inhibitor, possibly
as a result of cross-talk between the MAPK pathways.
Previous studies indicated that TNF production induced
upon M. tuberculosis infection was dependent on both
p38 and ERK1/2; on the other hand, MCP-1 production
was significantly up-regulated by a p38 inhibitor.22 In
addition, we demonstrated that PI3K activation was criti-
cal for TNF and MCP-1 production by monocytes in
response to Rv0652. These data are consistent with
another study in which PI3K was necessary for induction
of MCP-1 production in M. tuberculosis-stimulated
human monocytes.27 The other report also demonstrates
that mycobacteria trigger other intracellular signalling cas-
cades such as the PI3K pathway.28,29 These data demon-
strate that signal pathways triggered by Rv0652 in TNF
and MCP-1 production are similar to those by M. tuber-
culosis.
Toll-like receptors, particularly TLR2 and TLR4, recog-
nize M. tuberculosis and initiate macrophage responses
that influence both innate and adaptive immunity.30
Many mycobacterial components such as lipoarabinoman-
nan, 19 000-MW lipoprotein, and 38 000-MW glycolipo-
protein (PhoS1) also trigger secretion of pro-
inflammatory cytokines in a TLR2- and/or TLR4-depen-
dent manner.6 Although TLR2 appears to be the major
mediator of M. tuberculosis-induced cellular activation,
TLR4-activating components that appear to be heat labile
and cell-associated have been described.30 Most mycobac-
terial TLR2 agonists are lipoproteins or glycolipids, which
suggests that acylation is important for interaction with
TLR2.31 Recombinant mycobacterial heat-shock protein
70 expressed in E. coli signals through both TLR4 and
TLR2, whereas heat-shock protein 65 signals exclusively
through TLR4 to activate the innate immune system.32
Moreover, native 38 000-MW protein purified from
M. tuberculosis culture filtrate acts through both TLR2
and TLR4 to induce macrophage activation.10 The TLR4
generates signals in both MyD88-dependent and MyD88-
independent manners. To date, little is known about
mycobacterial proteins and glycolipids that signal exclu-
sively through TLR4.
The present study demonstrated that Rv0652 activates
macrophages to secrete TNF and MCP-1 in a TLR4-depen-
dent and MyD88-dependent manner. The similarity
between the cytokine patterns induced by Rv0652 and LPS
(Fig. 3) and the signalling of RV0652 chiefly through TLR4
suggested the possibility of LPS contamination in the pro-
tein preparation. However, several lines of evidence showed
that signalling via TLR4 and activation of macrophages
were attributable to Rv0652, and not to LPS contamina-
tion: no LPS was detected in purified Rv0652, the stimula-
tory effects of Rv0652 were abolished by boiling the
preparation or treating it with proteinase K, and polymyxin
B treatment did not suppress the effect of Rv0652.
Macrophages participate in anti-mycobacterial immu-
nity through the production of pro-inflammatory cyto-
kines or chemokines as well as by directly killing
M. tuberculosis within phagosomes. In addition, macro-
phages interact with T cells, which is a critical process for
the activation of both T cells and macrophages.3 In the
present study, we showed Rv0652-stimulated increases in
the expression of several macrophage surface molecules:
CD80 and CD86, which act as co-stimulators of T-cell
activation; MR, which participates in phagocytosis, and
MHC class II molecules, which are involved in antigen
presentation, were increased by Rv0652. The effects of
Rv0652 on the expression of these surface molecules were
more pronounced than those of LPS or immunodomi-
nant Ag85. The 19 000-MW protein activates macrophag-
es to secrete TNF and nitric oxide, but inhibits MHC II
antigen processing by macrophages.7,8 Rv2626c induces
pro-inflammatory cytokines and up-regulates various co-
stimulatory molecules such as CD80, CD86 and CD4.33
In light of these previous findings, our data indicate that
Rv0652 enhances the ability of macrophages to effectively
induce activation of T cells.
The interactions between M. tuberculosis and host mac-
rophages and the resultant host immune response are
complex processes that appear to involve diverse host and
bacterial molecules. Understanding the immunoregulatory
mechanisms of the mycobacterial components involved in
the pathogenesis of TB is critical for the development of
effective vaccines and more efficacious treatments for TB.
Rv0652 may play an immune-stimulatory role during
M. tuberculosis infection and may be a candidate for the
development of an immune-adjuvant.
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